Northwood facility loses appeal in N.S. class-action lawsuit over COVID-19 deaths
The Northwood Care Group has lost an appeal in a class-action lawsuit about the deaths of more than 50 people at a Halifax long-term care facility during the COVID-19 pandemic in 2020.
Northwood, according to a written decision by Justice Elizabeth Van den Eynden, sought an appeal in relation to an order certifying a class proceeding in the matter. On June 23, Van den Eynden denied the appeal and ordered Northwood to pay $800 to the plaintiff in the lawsuit.
The Supreme Court of Nova Scotia certified the class-action lawsuit last December.
According to Van den Eynden, the plaintiff Erica Surette filed an action for a proposed class of people whose next of kin tested positive for COVID-19 and died while staying at Northwood facilities between March 15, 2020, and June 30, 2020.
'During this period, 53 residents died after contracting COVID-19,' Van den Eynden's written decision reads. 'The statement of claim alleges Northwood owed legal duties to the deceased residents, breached those duties and the standard of care, and caused harm and damages as a result of the deaths.'
Ray Wagner, the lawyer representing the families in the lawsuit, says they are seeking damages for the loss of their loved ones.
'They want accountability, of course. They want to know why this happened,' Wagner told CTV News. 'Why didn't it happen in other long-term care facilities? Why did it only happen in Northwood?'
Van den Eynden said Northwood's appeal argued the Supreme Court judge erred by not applying a 'two-step method' in his analysis, which they claimed impacted the certification process.
'Northwood asserts, as it did before the motions judge, that the applicable test is a two-part framework which requires a plaintiff to demonstrate there is (1) some basis in fact that the proposed common issue actually exists; and (2) some basis in fact that the proposed issues are common to each class member,' the written decision reads. 'The test the judge employed was the equivalent to the second step.'
Van den Eynden ultimately ruled that Northwood did not raise a 'arguable issue' in its appeal.
'In my view, the judge applied the correct legal test, and even if he had adopted the two-part test advocated by Northwood, the result would have been the same given the unchallenged findings by the judge,' the decision reads.
-With files from CTV News Atlantic's Jesse Thomas
Patricia West
Northwood resident Patricia West died from COVID-19 on April 22, 2020. She was 66 years old. (Submitted: Erica Surette)
For more Nova Scotia news, visit our dedicated provincial page
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
Article content BOSTON & SCCT ANNUAL MEETING, MONTREAL — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has made two additions to its Board of Directors. The company named Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH as board directors. Article content These appointments will help guide Elucid as it accelerates its clinical research strategy, commercializes its flagship PlaqueIQ TM coronary plaque assessment technology, and continues development of its investigational FFR prediction model, based on PlaqueIQ. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. Article content An experienced medical technology executive and clinical expert, Dr. Kuntz is former senior vice president and chief medical and scientific officer of Medtronic plc. Prior to joining Medtronic, he was the founder and chief scientific officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization that coordinates National Institutes of Health (NIH) and industry clinical trials with the U.S. Food and Drug Administration (FDA). Dr. Kuntz has directed several multicenter clinical trials and has authored more than 250 original publications. Dr. Kuntz was an associate professor of Medicine at Harvard Medical School, chief of the division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women's Hospital in Boston. Article content Dr. Feinglass is a managing director at Manatt Health working across the business, medical, and policy needs of health systems, life sciences, medical device, digital health and diagnostic companies globally. A global leader in health care, Dr. Feinglass has served as an executive and chief medical officer in large multi-national life sciences corporations including Danaher and Zimmer-Biomet. In parallel, she has driven policy changes alongside senior government officials around the world to influence health policy, regulation, and access. A former regulator at U.S. Centers for Medicare and Medicaid Services (CMS) and commander in the U.S. Public Health Service with extensive regulatory and legislative experience, Dr. Feinglass is on faculty at the John's Hopkins Bloomberg School of Public Health, Department of Mental Health and is a member of the Board of Directors of Sandoz AG. Article content 'We are honored that Dr. Richard E. Kuntz and Dr. Shamiram Feinglass have joined Elucid's Board of Directors,' said Elucid CEO Kelly Huang, PhD. 'Rick lends an important and experienced interventional cardiology view, as well as expertise in clinical trial strategy and execution, and product innovation strategy. Coupled with Shami's unparalleled expertise in market access, policy making, and regulatory strategy, the two will be invaluable as we push forward our vision of a future where cardiac care is personalized, precision patient care versus risk factor and population-based care.' Article content About Elucid Article content Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Sam Choinski Article content Article content Article content Article content
CBC
2 hours ago
- CBC
How does wildfire smoke affect birds? This researcher is looking to find out
A researcher at the University of Saskatchewan wants to know how birds, particularly songbirds, are being impacted by wildfires and smoke. Catherine Ivy, a bird lover and assistant professor at the University of Saskatchewan college of arts and science, is leading the project. "I've always been interested in how birds are able to conduct their long migratory flights, and was interested in how animals change their breathing to deal with challenging environments," Ivy said. Canada's 2023 wildfire season was the worst on record in terms of area burned. The 2024 season was the second-worst since 1995. Ivy said there is anecdotal evidence that shows birds are being impacted by wildfire smoke, but there has never been research on the effects. One wildfire wouldn't have any adverse effect on birds, but repeated events and repeated exposure could. Ivy said there has been extensive research done on humans and lab animals. "We know from Health Canada and a whole bunch of other health funding bodies that being outside in the smoke is not good for us [humans]," she said. "But the one thing that research is kind of disregarded at the moment is what happens to wildlife that's outside." Ivy said this is important because it could help us be more aware of why bird populations are declining. She said we already know that changes to migratory routes, such as buildings where they didn't used to be, have had an impact. "But we don't know if wildfire smoke also adds on top of that," she said. "If wildfire smoke affects their lungs and affects their ability to migrate, it means that they might get stuck in environments that don't have enough resources for them during their southbound migration." She said the research will track migratory birds who fly long distances, and compare birds who have been exposed to wildfire smoke to those who haven't. "Health Canada tells us to stay inside, only breathe clean air," she said. "But these animals live outside all year round. So unfortunately we have this gap in our knowledge." The project received funding from the Natural Sciences and Engineering Research Council (NSERC) discovery grant program.
CTV News
2 hours ago
- CTV News
E-scooter injuries are on the rise among both kids and adults, data and doctors say
People cross Elgin Street on e-scooters in Ottawa, on Sunday, June 25, 2023. THE CANADIAN PRESS/Justin Tang TORONTO — The Canadian Institute for Health Information says e-scooter injuries are on the rise across the country. It released data Thursday saying that hospitalizations involving e-scooters for kids between five and 17 years old increased by 61 per cent from 2022-23 to 2023-24. The agency said hospitalizations for men between 18 and 64 went up by 22 per cent in that time period and went up by 60 per cent for women. The data shows the majority of e-scooter hospitalizations happened in Ontario, Quebec, Alberta and British Columbia. Dr. Daniel Rosenfield, a pediatric emergency physician at SickKids Hospital in Toronto, said the number of kids and teens arriving in the emergency department with e-scooter injuries has been increasing over the last five years and some have been 'catastrophic,' including one 13-year-old boy's death in 2023. 'We see anything from minor scrapes and cuts and little lacerations that need a couple of stitches to ... traumatic brain injury, internal bleeding in the chest and abdomen, open fractures that need to go to the operating room to be fixed,' he said. Some children between four and six years old have been hurt while riding with their parents on an e-scooter, Rosenfield said, but injuries among teens riding on their own is more common. Among cases where the information is available, 80 per cent of the riders who end up in the ER aren't wearing helmets, he said. Rosenfield said he thinks the rise in injuries correlates to an increase in the popularity and affordability of e-scooters in recent years — together with a lack of understanding about how dangerous they can be. 'These scooters, much like everything electrified these days, have come down in price and have increased in power,' he said. 'Their acceleration and torque is tremendous. And most parents, when they're buying these things for their kids, are completely unaware of that.' Pamela Fuselli, president and CEO of Parachute Canada — a charity focused on injury prevention — said the laws around e-scooters vary between provinces and even municipalities. In Ontario, riders must be at least 16 years old. But in Toronto, e-scooters are not allowed on public roads or paths. And just east of the city in Oshawa, they're permitted under a pilot program. But people are clearly using them even where they're not allowed, Fuselli said. 'Even while a city may have a bylaw about this, they can regulate what's operated in public spaces, but then that has to be enforced. They can't really regulate what's sold,' she said. Fuselli said kids under 16 should not be riding e-scooters — and parents shouldn't be buying them for children younger than that. 'They look like toys, but they really are motor vehicles,' she said. This report by The Canadian Press was first published July 17, 2025. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Nicole Ireland, The Canadian Press
